Charles River Unveils Non-Human Protein Library With Retrogenix®

Charles River Laboratories International, Inc. has announced the launch of the Retrogenix® Non-Human Protein Library, aimed at helping biopharmaceutical clients assess off-target binding in non-human proteomes, reducing risks involved in in-vivo studies and aiding species selection for testing. 

Aidan Synnott, PhD, Corporate Vice President, Global Discovery, said in a statement, “Developed in-house using the innovative and unique Retrogenix® platform, the new library provides early insights into how therapeutics interact with non-human protein targets in vitro. These early insights are generated without the lead time and expense associated with ex vivo tissue or in vivo research model studies, allowing clients to progress to safety studies, clinical trials, and IND applications with highly relevant data and increased confidence.” 

By determining whether off-targets are protected across species, the tool enhances the interpretability of in-vivo results. It ensures that safety studies are conducted using the appropriate model from the outset.

In addition to the new library, Charles River can also observe human off-targets when compared to suitable non-human homologous proteins to provide crucial insights for drug development to guide clients.